33 01/04/2024 31/03/2025 2025-03-31 false false false false false false false true false false true false false false false false false false No description of principal activities is disclosed 2024-04-01 Sage Accounts Production 24.0 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 03176158 2024-04-01 2025-03-31 03176158 2025-03-31 03176158 2024-03-31 03176158 2023-04-01 2024-03-31 03176158 2024-03-31 03176158 2023-03-31 03176158 bus:Director1 2024-04-01 2025-03-31 03176158 core:IntangibleAssetsOtherThanGoodwill 2024-03-31 03176158 core:IntangibleAssetsOtherThanGoodwill 2025-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2024-03-31 03176158 core:PlantMachinery 2024-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2025-03-31 03176158 core:PlantMachinery 2025-03-31 03176158 core:DeferredTaxation 2024-04-01 2025-03-31 03176158 core:WithinOneYear 2025-03-31 03176158 core:WithinOneYear 2024-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2024-04-01 2025-03-31 03176158 core:PlantMachinery 2024-04-01 2025-03-31 03176158 core:ShareCapital 2025-03-31 03176158 core:ShareCapital 2024-03-31 03176158 core:CapitalRedemptionReserve 2025-03-31 03176158 core:CapitalRedemptionReserve 2024-03-31 03176158 core:RetainedEarningsAccumulatedLosses 2025-03-31 03176158 core:RetainedEarningsAccumulatedLosses 2024-03-31 03176158 core:BetweenOneFiveYears 2025-03-31 03176158 core:BetweenOneFiveYears 2024-03-31 03176158 core:MoreThanFiveYears 2025-03-31 03176158 core:MoreThanFiveYears 2024-03-31 03176158 core:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 03176158 core:IntangibleAssetsOtherThanGoodwill 2024-03-31 03176158 core:CostValuation core:Non-currentFinancialInstruments 2024-03-31 03176158 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 03176158 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 03176158 core:Non-currentFinancialInstruments 2025-03-31 03176158 core:Non-currentFinancialInstruments 2024-03-31 03176158 core:AcceleratedTaxDepreciationDeferredTax 2025-03-31 03176158 core:AcceleratedTaxDepreciationDeferredTax 2024-03-31 03176158 core:LandBuildings core:ShortLeaseholdAssets 2024-03-31 03176158 core:PlantMachinery 2024-03-31 03176158 core:DeferredTaxation 2024-03-31 03176158 core:DeferredTaxation 2025-03-31 03176158 bus:SmallEntities 2024-04-01 2025-03-31 03176158 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 03176158 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 03176158 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 03176158 bus:FullAccounts 2024-04-01 2025-03-31 03176158 core:FinancialAssetsFairValueThroughProfitOrLossDeferredTax 2025-03-31 03176158 core:FinancialAssetsFairValueThroughProfitOrLossDeferredTax 2024-03-31
Company registration number: 03176158
HOME HEALTH (U.K.) LIMITED
Unaudited filleted financial statements
31 March 2025
HOME HEALTH (U.K.) LIMITED
Contents
Statement of financial position
Notes to the financial statements
HOME HEALTH (U.K.) LIMITED
Statement of financial position
31 March 2025
2025 2024
Note £ £ £ £
Fixed assets
Intangible assets 6 475 50
Tangible assets 7 15,512 26,512
Investments 8 813,876 741,423
_______ _______
829,863 767,985
Current assets
Stocks 2,155,597 2,610,716
Debtors 9 954,142 813,861
Cash at bank 1,122,068 1,032,632
_________ _________
4,231,807 4,457,209
Creditors: amounts falling due
within one year 10 ( 659,632) ( 777,207)
_______ _______
Net current assets 3,572,175 3,680,002
_________ _________
Total assets less current liabilities 4,402,038 4,447,987
Provisions for liabilities 11 ( 32,281) ( 17,015)
_________ _________
Net assets 4,369,757 4,430,972
_________ _________
Capital and reserves
Called up share capital 50 50
Capital redemption reserve 50 50
Profit and loss account 4,369,657 4,430,872
_________ _________
Shareholders funds 4,369,757 4,430,972
_________ _________
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 28 July 2025 , and are signed on behalf of the board by:
Mr J R Baxter
Director
Company registration number: 03176158
HOME HEALTH (U.K.) LIMITED
Notes to the financial statements
Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Chancellors House, Brampton Lane, London, NW4 4AB.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities measured at fair value through profit or loss. The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Operating leases
Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.
Intangible assets
Intangible assets are initially recorded at cost, and are subsequently stated at cost less accumulated amortisation and impairment losses. Trade marks are amortised over ten years on a straight line basis.
Tangible assets
Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Leasehold improvements - Straight line over ten years (period of the lease)
Plant and machinery - 25% reducing balance
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Fixed asset investments
Listed investments are measured at fair value with changes in the fair value being recognised in profit or loss.
Stocks
Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided.
Foreign currencies
Transactions in foreign currencies are recorded in sterling at the exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the exchange rate prevailing at the reporting date. All exchange gains or losses are taken as profit or loss.
Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable, amounts receivable or payable to related parties and other third parties. Debt instruments that are receivable or payable within one year, such as trade receivables and payables are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be received or paid. Listed investments are measured at fair value with changes in the fair value being recognised in profit or loss.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 33 (2024: 35 ).
5. Income from other fixed asset investments
2025 2024
£ £
Dividends from listed investments 38,370 32,843
Gain on fair value adjustments-listed investments 72,067 43,496
_______ _______
110,437 76,339
_______ _______
6. Intangible assets
Other intangible assets Total
£ £
Cost
At 1 April 2024 1,020 1,020
Additions 500 500
_______ _______
At 31 March 2025 1,520 1,520
_______ _______
Amortisation
At 1 April 2024 970 970
Charge for the year 75 75
_______ _______
At 31 March 2025 1,045 1,045
_______ _______
Carrying amount
At 31 March 2025 475 475
_______ _______
At 31 March 2024 50 50
_______ _______
7. Tangible assets
Short leasehold property Plant and machinery Total
£ £ £
Cost
At 1 April 2024 56,263 30,570 86,833
Disposals ( 2,196) ( 4,237) ( 6,433)
_______ _______ _______
At 31 March 2025 54,067 26,333 80,400
_______ _______ _______
Depreciation
At 1 April 2024 42,288 18,033 60,321
Charge for the year 7,140 3,028 10,168
Disposals ( 1,791) ( 3,810) ( 5,601)
_______ _______ _______
At 31 March 2025 47,637 17,251 64,888
_______ _______ _______
Carrying amount
At 31 March 2025 6,430 9,082 15,512
_______ _______ _______
At 31 March 2024 13,975 12,537 26,512
_______ _______ _______
8. Investments
Shares in Home Health US, Inc. Listed investments Total
£ £ £
Cost
At 1 April 2024 - 741,423 741,423
Additions 386 - 386
Fair value adjustment - 72,067 72,067
_______ _______ _______
At 31 March 2025 386 813,490 813,876
_______ _______ _______
Impairment
At 1 April 2024 and 31 March 2025 - - -
_______ _______ _______
Carrying amount
At 31 March 2025 386 813,490 813,876
_______ _______ _______
At 31 March 2024 - 741,423 741,423
_______ _______ _______
Home Health US, Inc. is a wholly owned subsidiary of Home Health (U.K.) Limited.
9. Debtors
2025 2024
£ £
Trade debtors 702,221 456,057
Amounts owed by Home Health US, Inc. (group undertaking) 168,252 172,459
Other debtors 83,669 185,345
_______ _______
954,142 813,861
_______ _______
10. Creditors: amounts falling due within one year
2025 2024
£ £
Trade creditors 322,018 356,205
Corporation tax 95,622 121,520
Social security and other taxes 161,203 267,231
Other creditors 80,789 32,251
_______ _______
659,632 777,207
_______ _______
11. Provisions
Deferred tax (note 12) Total
£ £
At 1 April 2024 17,015 17,015
Additions 15,266 15,266
_______ _______
At 31 March 2025 32,281 32,281
_______ _______
12. Deferred tax
The deferred tax included in the statement of financial position is as follows:
2025 2024
£ £
Included in provisions (note 11) 32,281 17,015
_______ _______
The deferred tax account consists of the tax effect of timing differences in respect of:
2025 2024
£ £
Accelerated capital allowances 3,878 6,628
Fair value adjustment of financial assets 28,403 10,387
_______ _______
32,281 17,015
_______ _______
13. Operating leases
The company as lessee
The total future minimum lease payments under non-cancellable operating leases are as follows:
£ £
Not later than 1 year 156,937 156,937
Later than 1 year and not later than 5 years 591,646 613,583
Later than 5 years 123,750 258,750
_______ _________
872,333 1,029,270
_______ _________